par Van Cutsem, Eric;Li, C. P.;Nowara, Elzbieta;Aprile, G;Moore, Malcolm J;Federowicz, I;Van Laethem, Jean-Luc 
;Hsu, C;Tham, C K;Stemmer, S M;Lipp, R;Zeaiter, A;Fittipaldo, A;Csutor, Z;Klughammer, B;Meng, X;Ciuleanu, T
Référence British Journal of Cancer, 111, 11, page (2067-2075)
Publication Publié, 2014-11
;Hsu, C;Tham, C K;Stemmer, S M;Lipp, R;Zeaiter, A;Fittipaldo, A;Csutor, Z;Klughammer, B;Meng, X;Ciuleanu, TRéférence British Journal of Cancer, 111, 11, page (2067-2075)
Publication Publié, 2014-11
Article révisé par les pairs
| Résumé : | This phase II, open-label, randomised study evaluated whether patients with metastatic pancreatic cancer receiving erlotinib/gemcitabine derived survival benefits from increasing the erlotinib dose. |
